MOMA Therapeutics operates as a biotechnology company.
MOMA Therapeutics has raised $150.0M in total funding. The most recent round was Series B. The last funding was announced in May 2022.
MOMA Therapeutics's investors include Cormorant Asset Management, Third Rock Ventures, S32, Goldman Sachs Asset Management, Alexandria Venture Investments.
MOMA Therapeutics is headquartered in Cambridge, United States.
MOMA Therapeutics operates as a biotechnology company.
MOMA Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MOMA Therapeutics — Funding & Investors." VCBacked, May 10, 2022, https://www.vcbacked.co/company/moma-therapeutics. Accessed September 13, 2026.
VCBacked. (2022). MOMA Therapeutics — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/moma-therapeutics
{{cite web |title=MOMA Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/moma-therapeutics |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated